AnX Robotica, a prominent leader in the field of medical technology, has recently obtained the anticipated FDA clearance for its revolutionary artificial intelligence (AI)-assisted reading tool, NaviCam ProScan. This state-of-the-art technology has been developed to aid in small bowel capsule endoscopy, particularly for adult patients who are suspected of experiencing gastrointestinal bleeding.
Gastrointestinal bleeding is a critical indicator of an underlying disorder within the digestive tract, and can be linked to a range of conditions such as haemorrhoids, peptic ulcers, tears, or inflammation in the oesophagus. The FDA clearance of NaviCam ProScan signifies a significant milestone in the realm of gastroenterology, providing healthcare professionals with an advanced tool to bolster their diagnostic and treatment decisions.
Initially introduced in February of the previous year, ProScan is aimed at enhancing the efficacy of capsule endoscopy by providing physicians and clinicians with cutting-edge AI technology. It is important to note that ProScan is not intended to supplant the clinical judgment of healthcare professionals, but rather to support them in making well-informed decisions for their patients.
A pivotal component of this innovative tool is its AI-assisted reading capability, which has been proven to notably enhance the accuracy of diagnostic readings. A groundbreaking study that was published in Gastroenterology demonstrated that ProScan, following training with over 150,000 images collected from 1,971 patients, was able to identify abnormal images with an impressive sensitivity of 99.88% in per-patient analysis and 99.90% in per-lesion analysis.
Stu Wildhorn, the Vice President of Marketing and Product Management at AnX Robotica, expressed the company’s delight at the FDA clearance of the software, emphasising the potential of ProScan to significantly improve diagnostic workflows and enable clinicians to make well-informed decisions in a timely manner. This clearance represents a substantial progression in the company’s mission to elevate patient care standards through technological innovation.
Dr Cristiano Spada, a distinguished professor of gastroenterology and director of endoscopy and digestive surgery at Gemelli Hospital, also offered his perspective on this pivotal advancement, highlighting the potential of the AI-assisted reading tool to revolutionise small bowel capsule endoscopy and usher in a new era of gastroenterological diagnostics.
Furthermore, AnX Robotica’s future plans involve expanding the NaviCam platform to incorporate additional visualization aids and therapeutic applications, with the ultimate goal of providing comprehensive solutions for various diagnostic and treatment needs. The company’s innovative spirit and commitment to advancing medical technology are further demonstrated by its existing products such as the NaviCam Colon System in Europe and the IntraMarX 3D in the US, which are geared towards enhancing colonic transit studies.
The FDA clearance of NaviCam ProScan undeniably stands as a significant achievement for AnX Robotica, and it lays the groundwork for a new era of AI-driven innovation in gastrointestinal diagnostics. As the healthcare industry continues to embrace cutting-edge technologies, it is crucial for companies like AnX Robotica to establish the standard for excellence and lead the way in improving patient care through advanced medical solutions.
+ There are no comments
Add yours